Targeted therapy of polycytemia vera patients

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• The JAK2V617F mutation is central to the pathophysiology of Philadelphia chromosome-negative myeloproliferative neoplasms (MPN).
• This mutation has emerged as a critical therapeutic target, particularly in polycythemia vera (PV).

Purpose of the Study:

• To review the molecular-genetic basis of polycythemia vera (PV) pathogenesis.
• To explore novel therapeutic strategies, specifically JAK inhibitors, for PV treatment.
• To assess the efficacy and safety of JAK inhibitors in patients resistant or intolerant to standard therapies.

Main Methods:

• Literature review of molecular-genetic features in PV pathogenesis.
• Review of studies on JAK inhibitors as targeted therapy for PV.
• Analysis of clinical trial data, including the RESPONSE trial for ruxolitinib.

Main Results:

• JAK2 mutation identification opened new avenues for understanding and treating Ph-negative MPN.
• JAK inhibitors represent a significant advancement in targeted therapy for PV.
• Ruxolitinib demonstrated efficacy and safety in clinical trials for PV patients.

Conclusions:

• Targeted therapy with JAK inhibitors offers improved outcomes and quality of life for PV patients.
• Understanding JAK2 mutation is key to developing effective treatments for MPN.
• JAK inhibitors are a promising alternative for patients with hydroxycarbamide or interferon-refractory PV.